ESC 2026: enlicitide extends oral PCSK9 benefits beyond LDL-C lowering

At ESC 2026 Scientific Sessions, Phase III data were presented evaluating the Lp(a)-lowering efficacy of MSD’s Lipfendra (enlicitide). Enlicitide strengthens its oral PCSK9 profile with substantial LDL-C lowering and additional reductions in Lp(a). Credit: Sergiy Palamarchuk / Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise. Hard data and deep insights on clinical trials strategy & operations

Source: Clinical Trials Arena